- Home
- BFST vs INBX Comparison
BFST vs INBX Comparison
Compare BFST & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BFST | INBX |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 877.1M | 999.7M |
| IPO Year | 2014 | 2024 |
Fundamental Metrics
Financial Performance| Metric | BFST | INBX |
|---|---|---|
| Price | $27.98 | $100.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | $32.75 | ★ $150.00 |
| AVG Volume (30 Days) | 141.8K | ★ 489.3K |
| Earning Date | 04-27-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | ★ 23.45 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $10,704,000.00 | $1,300,000.00 |
| Revenue This Year | $22.71 | N/A |
| Revenue Next Year | $5.02 | N/A |
| P/E Ratio | $41.16 | ★ N/A |
| Revenue Growth | 1.20 | ★ 550.00 |
| 52 Week Low | $22.56 | $12.80 |
| 52 Week High | $30.32 | $155.29 |
Technical Indicators
Market Signals| Indicator | BFST | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 55.01 | 45.50 |
| Support Level | $26.73 | $99.20 |
| Resistance Level | $28.74 | $153.14 |
| Average True Range (ATR) | 0.53 | 13.75 |
| MACD | 0.08 | -3.93 |
| Stochastic Oscillator | 75.72 | 8.06 |
Price Performance
Historical ComparisonAbout BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates the majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.